Brazilian version of "the insulin delivery system rating questionnaire": translation, cross-cultural adaptation and validation

• Autor(a) principal: Raquel Cristina Lopes Assis Coelho
• Data de Publicação: 2020
• Outros Autores: Aleida Nazareth Soares, Janice Sepulveda Reis, Adriana Silvina Pagano
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.20945/2359-3997000000274; http://hdl.handle.net/1843/47490; https://orcid.org/0000-0001-5073-2443; https://orcid.org/0000-0002-3150-3503; https://orcid.org/0000-0002-2671-3661; https://orcid.org/0000-0002-2465-862X
• topic: Translation; Cultural adaptation; Diabetes Mellitus; Insulin; Health related quality of life; Lingüística; Diabetes

Objective: The aim of this study was to translate and cross-culturally adapt the Insulin Delivery System Rating Questionnaire (IDSRQ) for Brazilian users. Validation and reliability analysis of measures were also performed. Materials and methods: Methodological study comprising the following stages: forward translation, synthesis, back-translation, assessment by Expert Committee, pre-test and validation. International guidelines for translation and cross-cultural adaptation of measurement tools were followed. Validation data provided information about reliability (internal consistency, testretest) and construct validity of the IDSRQ. Results: Content validation by Experts’ assessment was successful, with a mean Content Validity Index of 0.87 (±0.2). The IDSRQ validation study involved 113 T1DM patients, 46% male, mean age 32.61 (±12.59) years and mean age at diagnosis of diabetes of 17.51 (±12.41). The scale presented good internal consistency (Cronbach’s alpha =0.786). The reliability analysis of the instrument was conducted by calculating the Intra-class Correlation Coefficient 0.885 (0.834-0.921), which indicated adequate concordance in all measures. Conclusion: The translated and cross-culturally adapted Brazilian Portuguese version of the IDSRQ may be used to assess health-related quality of life (HRQOL) and treatment preferences for insulin delivery systems in T1DM Brazilian patients.